New RT journal calls for papers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts.

Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts. Manuscripts should focus on imaging, contouring, target delineation, simulation, treatment planning, immobilization, organ motion, patient safety, and quality measurement.

W. Robert Lee, MD, has been named editor of Practical Radiation Oncology. Dr. Lee is a professor in the department of radiation oncology and program director of the radiation oncology training program at Duke University in Durham, N.C. Visit ees.elsevier.com/practicalradonc/ to submit a manuscript.

Articles in this issue
PSA test drives diagnosis within families
New RT journal calls for papers
Oral Bisphosphonates Not Linked to Esophageal Cancer Risk
Partnering of chemotherapy and radiation yields great response rates in H&N ca, but has not improved survival
Should radiation therapy plus hormone therapy be the new standard of care for locally advanced prostate cancer?
Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma
Ipilimumab put on fast track by FDA
Who's News
ASTRO releases breast RT guide
Research chair named after Dr. Salem
Breast Cancer Specialists Brace for FDA Word on Avastin
Influx of Funding Impels Collaborative Explorations to Study Sarcoma as Behavior Model for Other Cancers
ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
Study supports earlier colon cancer screening for men, but not African Americans
Bone marrow procedures move into the 21st century
Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
Related Content
Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tim Cortese
February 21st 2025
Article

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Improving End-of-Life Care in ICD Users With Advanced Cancers

Megan Mullins, PhD, MPH
February 20th 2025
Article

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.